AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01595854
Drug: dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medium dose dabigatran
Trial: NCT01595854
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high dose ticagrelor
Trial: NCT04521322
Drug: Iota-Carrageenan
RxNorm normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days
Trial: NCT03573323
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT03573323
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT01595854
Drug: dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose dabigatran
Trial: NCT00079183
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00413218
Drug: Isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion.
Trial: NCT00413218
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion.
Trial: NCT00413218
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion.
Trial: NCT00435799
Drug: Riboflavin/dextran eyedrops
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00956306
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Single Oral Dose of Udenafil
Trial: NCT02855268
Drug: lademirsen (SAR339375)
RxNorm normalized name: Lademirsen
DrugBank: Lademirsen (DB17611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection
Trial: NCT03202563
Drug: Gemigliptin 50mg
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
Trial: NCT03202563
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)\~Visit 6(day 91))
Trial: NCT03202563
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
Trial: NCT01543074
Drug: BSE
RxNorm normalized name: Ebselen
DrugBank: Ebselen (DB12610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 pills = 200 micromoles of Sulforaphane/day
Trial: NCT03312335
Drug: Low-dose Aldesleukin (Proleukin®)
RxNorm normalized name: ethinyl estradiol
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
Trial: NCT05038072
Drug: suprachoroidal injection of Triamcinolone Acetonide.
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg /0.1 ml TA was injected in the SCS using an individualized microinjector according to scleral thickness measured by anterior segment OCT (AS-OCT) at the injection point (4 mm from the limbus in the inferotemporal quadrant).
Trial: NCT00755781
Drug: Cyclosporine Inhalation Solution (CIS)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
Trial: NCT00754936
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg by mouth daily
Trial: NCT00436644
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1250 mg orally days 1 -28.
Trial: NCT00436644
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
Trial: NCT02845856
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
Trial: NCT01064804
Drug: PF-04191834
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04191834. 100mg Immediate Release Tablets or oral suspension
Trial: NCT00005840
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00005840
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03743246
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine
Trial: NCT04505943
Drug: Isonicotinic Acid Hydrazide
RxNorm normalized name: Isonicotinic acid hydrazide
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 vaginal tablet of isonicotinic acid hydrazide inserted by the study nurse12 hours before IUD insertion.
Trial: NCT04505943
Drug: dinoprostine
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprost (DB12789)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
Trial: NCT04505943
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion
Trial: NCT00979056
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg per day, oral use, maximum duration 28 days
Trial: NCT01490580
Drug: atropine+ propofol
RxNorm normalized name: Propofol
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg
Trial: NCT00986843
Drug: HM30181AK tablet + Irinotecan tablets
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
Trial: NCT01814475
Drug: A: Fludarabine + Busulphan
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
Trial: NCT01814475
Drug: B: Fludarabine + Thiotepa
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
Trial: NCT02873754
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
Trial: NCT02873754
Drug: Transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
Trial: NCT00003304
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01892241
Drug: Pegasys(Roche)
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
Trial: NCT01892241
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continual entecavir therapy(0.5 mg orally once daily)
Trial: NCT01961271
Drug: Buprenorphine transdermal patch
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Please see Arm Description.
Trial: NCT00056979
Drug: Anti-CD45
RxNorm normalized name: 131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I
DrugBank: Apamistamab iodine I-131 (DB16748)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00056979
Drug: FK506
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02873754
Drug: Nicotine polacrilex
RxNorm normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
Trial: NCT00056979
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02873754
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
Trial: NCT01849562
Drug: Sovaprevir
RxNorm normalized name: Sovaprevir
DrugBank: Sovaprevir (DB12069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonstructural protein 3/4A protease inhibitor.
Trial: NCT00972504
Drug: Cetirizine 10mg
RxNorm normalized name: CETIRIZINE 10MG/ML INJ
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine 10mg active comparator
Trial: NCT01849562
Drug: ACH-3102
RxNorm normalized name: ACh
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonstructural protein 5A inhibitor.
Trial: NCT01749969
Drug: isatuximab SAR650984
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution Route of administration: intravenous
Trial: NCT00909935
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
Trial: NCT00866554
Drug: administration of a LHRH agonist and Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
Trial: NCT01749969
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:capsules Route of administration: oral
Trial: NCT01749969
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
Trial: NCT00005857
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01300312
Drug: Eperisone hydrochloride
RxNorm normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
Trial: NCT00866554
Drug: administration of Bicalutamide, Dutasteride and Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered.
Trial: NCT01849562
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01854970
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
Trial: NCT02028533
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00017511
Drug: cevimeline hydrochloride
RxNorm normalized name: Cevimeline Hydrochloride
DrugBank: Cevimeline (DB00185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03740659
Drug: Levofloxacin + Dexamethasone
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
Trial: NCT03740659
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
Trial: NCT03740659
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
Trial: NCT01394211
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02114463
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine
Trial: NCT03498170
Drug: Itraconazole 200 mg
RxNorm normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of itraconazole
Trial: NCT03432780
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01394211
Drug: pazopanib hydrochloride
RxNorm normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02304419
Drug: Galunisertib
RxNorm normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00380705
Drug: MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00269880
Drug: Abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
Trial: NCT01453933
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
Trial: NCT02779608
Drug: intraperitoneal docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
Trial: NCT02779608
Drug: oral S-1
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/m² twice daily on day 1-14 every 3 weeks
Trial: NCT02724085
Drug: TP-271
RxNorm normalized name: TP-271
DrugBank: TP-271 (DB15040)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
Trial: NCT05561036
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline solution
Trial: NCT02914522
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Tablet(s) administered orally once daily
Trial: NCT01789710
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
Trial: NCT01789710
Drug: Nicotine replacement therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
Trial: NCT02914522
Drug: PTM filgotinib
RxNorm normalized name: Nilotinib
DrugBank: Filgotinib (DB14845)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet(s) administered orally once daily
Trial: NCT00171002
Drug: valsartan/amlodipine
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01187628
Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931)
RxNorm normalized name: Fosrenol
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
Trial: NCT00607087
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Trial: NCT00607087
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Trial: NCT00607087
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Trial: NCT00279916
Drug: Triamcinolone acetonide nasal spray
RxNorm normalized name: triamcinolone acetonide Metered Dose Nasal Spray
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms).
Trial: NCT02874326
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004141
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004141
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004141
Drug: Granulocyte-macrophage colony-stimulating factor
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01141322
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
Trial: NCT03292315
Drug: Semaglutide 1MG Injection [Ozempic]
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once weekly injection of 1mg of Semaglutide.
Trial: NCT00633360
Drug: Drospirenone and ethinyl estradiol
RxNorm normalized name: DROSPIRENONE AND ETHINYL ESTRADIOL KIT
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once daily by mouth